Home MarketDr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. Stock Info: As on 2017-07-26 15:53:37

Nse

838.35

-1.00(-0.12%)
Change%
52 Week Range
762.15
3.00
1,280.00
21.00
Open842.05
Day's Range671.48 - 1,007.22
Value Traded (in ₹ Cr.) 2.89

Bse

840.95

4.00(0.48%)
Change %
52 Week Range
762.70
3.00
1,278.55
21.00
Open841.00
Day's Range669.56 - 1,004.34
Value Traded (in ₹ Cr.) 0.16

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 48,265,226.00 57.92%
Mutual Funds/UTI 5,168,647.00 6.20%
FII 8,820,587.00 10.58%
Employee 0.00 0.00%
Public 3,470,275.00 4.16%
Government 0.00 0.00%
Others 15,293,892.00 18.35%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 9.95
Basic EPS (Rs.) 15.31
Cash EPS 19.08
BVPerShare Excl 57.88
Operating Revenue 92.58
PBDITPerShare 27.12
Dividend 2.45
NPPerShare 15.21
Current Ratio 4.68
Quick Ratio 4.52
PriceToBV 15.92
Earnings 0.01
PBDIT Margin 29.29
PBT Margin 25.05
NP Margin 16.42
Return On Assets 21.25
Retention Ratios 83.87
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 785.81
Total Expenses 594.05
EBITDA 224.25
PBT 191.75
PAT 125.75
Net Income 125.75
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 384.69
Total Expenses 268.78
EBITDA 99.39
PBT 132.23
PAT 92.43
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 82.68
Net worth 478.51
Investments 74.18
Total Liability 591.72
Total debt 0.00
Net block 133.88
Total Assets 591.72
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 81.26
Net worth 319.24
Investments 49.36
Total Liability 449.18
Total debt 0.00
Net block 119.97
Total Assets 449.18
Company Curr Price Prev. Close Change% W's Low/High

Apollo Hospitals Enterprise Ltd.

1292.75 1294.3 -0.12
1230.051312

Fortis Healthcare Ltd.

166.25 168.65 -1.42
151.45170.35

Healthcare Global Enterprises Ltd.

271.95 270.5 0.54
263.3275

Indraprastha Medical Corporation Ltd.

57.85 57.95 -0.17
55.2560.85

Kovai Medical Center and Hospital Ltd.

641.65 624.85 2.68
629.9649.9

Lotus Eye Hospital and Institute Ltd.

40.7 39.35 3.43
3640.9

Marico Kaya Enterprises Ltd.

1547.05 1582.55 -2.24
1535.051589
Company Curr Price Prev. Close Change% W's Low/High

ADS Diagnostic Ltd.

11.34 10.8 0
11.3411.34

Apollo Hospitals Enterprise Ltd.

1289.95 1288.55 0.11
1226.41310

Birla Pacific Medspa Ltd.

0.28 0.27 0
0.270.28

CDR Health Care Ltd.

7.58 2.6 0
7.227.58

Chennai Meenakshi Multispeciality Hospital Ltd.

11.4 11.5 -0.87
11.411.4

Dhanvantri Jeevan Rekha Ltd.

40 38.4 4.17
36.540.3

Dolphin Medical Services Ltd.

1.38 1.45 -4.83
1.251.52
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 142.25
Cash from investing activities -148.14
Cash from financing activities 0.99
Net change in cash -4.89

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Magnum Balanced Fund 1.04%
SBI Blue Chip Fund 0.49%
SBI Magnum Midcap Fund 1.62%
Franklin India Prima Plus 0.50%
SBI Magnum Global Fund 1.78%
SBI Pharma Fund 3.36%

Adlabs Entertainment posts Q1 net loss of Rs 22.51 cr

Net revenue of the company rose marginally by 4.24 per cent at Rs 86.62 crore for the quarter ended June 30, 2017 as against Rs 83.10 crore in the corresponding period last year. During Apr-Jun quarter, operating expenses dropped by 2.39 per cent to Rs 54.39 crore from Rs 55.72 in year ago period. Other Income dipped by 33.33 per cent at Rs 0.16 crore versus (Jun'16 Rs 0.24 crore). Operating Profit surged by 6.62 per cent to Rs 32.23 crore as against Rs 30.23 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 2.25 per cent in Jun quarter. Interest grew by 9.52 per cent y-o-y to Rs 31.97 crore. On the standalone basis, Net loss during the quarter stood at Rs 22.51 crore as compared to net loss of Rs 19.23 crore in the previous year quarter.

26-07-2017 17:45

NCLT appoints IRP for Nagarjuna Oils Corporation

Nagarjuna Oil Refinery Ltd (NOCL) today said the National Company Law Tribunal (NCLT), Chennai, has appointed an Insolvency Resolution Professional (IRP) for NOCL. The NCLT passed the order yesterday based on an application filed by the creditors, it said. We have to inform you that under the Insolvency and Bankruptcy Code, 2016, an Insolvency Resolution Professional (IRP) has been appointed by National Company Law Tribunal, on July 25, 2017 for Nagarjuna Oil Corporation Ltd based on an application filed by one of its creditors, NORL said in a filing with bourses. NORL holds 46.78 per cent of the equity share capital in NOCL, which is involved in setting-up a refinery at Cuddalore in Tamil Nadu. The company shall be entitled to take any proposal before the IRP during the period of six months or such extension that may be permitted in the event an investor is identified to take the project forward, the filing further said. Meanwhile, shares of the company closed trading at Rs 4.55 apiece, up 8.59 per cent from the previous close on BSE.

26-07-2017 17:29

Ion Exchange (India) Q1 net profit up 8.32% at Rs 7.29 cr

Net revenue of the company rose moderately by 9.56 per cent at Rs 208.05 crore for the quarter ended June 30, 2017 as against Rs 189.90 crore in the corresponding period last year. During Apr-Jun quarter, operating expenses increased by 10.02 per cent to Rs 196.18 crore from Rs 178.32 in year ago period. Other Income grew by 59.55 per cent at Rs 5.68 crore versus (Jun'16 Rs 3.56 crore). Operating Profit slipped by 0.92 per cent to Rs 11.87 crore as against Rs 11.98 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 9.51 per cent in Jun quarter. Interest grew by 20.75 per cent y-o-y to Rs 3.20 crore, while Taxation increased by 6.69 per cent at Rs 3.83 crore (Jun'16 Rs 3.59 crore). On the standalone basis, Net Profit during the quarter increased by 8.32 per cent to Rs 7.29 crore from Rs 6.73 crore in the previous year quarter.

26-07-2017 17:20

G G Automotive Gears Q1 net profit zooms 106.67%

Net revenue of the company rose substantially by 45.42 per cent at Rs 8.10 crore for the quarter ended June 30, 2017 as against Rs 5.57 crore in the corresponding period last year. During Apr-Jun quarter, operating expenses increased by 42.25 per cent to Rs 7.07 crore from Rs 4.97 in year ago period. Other Income grew by 0.00 per cent at Rs 0.01 crore versus (Jun'16 Rs 0.00 crore). Operating Profit surged by 54.55 per cent to Rs 1.02 crore as against Rs 0.66 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 6.94 per cent in Jun quarter. Interest grew by 73.33 per cent y-o-y to Rs 0.26 crore, while Taxation increased by 100.00 per cent at Rs 0.06 crore (Jun'16 Rs 0.03 crore). On the standalone basis, Net Profit during the quarter increased by 106.67 per cent to Rs 0.31 crore from Rs 0.15 crore in the previous year quarter.

26-07-2017 17:15

Agro Tech Foods Ltd. Q1 net profit up 5.86% at Rs 6.50 cr

Net revenue of the company declined marginally by 1.80 per cent at Rs 187.16 crore for the quarter ended June 30, 2017 as against Rs 190.60 crore in the corresponding period last year. During Apr-Jun quarter, operating expenses dropped by 1.64 per cent to Rs 173.19 crore from Rs 176.08 in year ago period. Other Income dipped by 50.00 per cent at Rs 0.02 crore versus (Jun'16 Rs 0.04 crore). Operating Profit slipped by 3.31 per cent to Rs 14.61 crore as against Rs 15.11 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 1.51 per cent in Jun quarter. Interest declined by 88.51 per cent y-o-y to Rs 0.20 crore, while Taxation increased by 19.14 per cent at Rs 3.61 crore (Jun'16 Rs 3.03 crore). On the standalone basis, Net Profit during the quarter increased by 5.86 per cent to Rs 6.50 crore from Rs 6.14 crore in the previous year quarter.

26-07-2017 17:10

Dr. Lal Pathlabs Ltd - Updates

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Disclosure under Reg. 30 of SEBI (LODR) Regulations, 2015

24-Jul-2017 12:56 PM

Dr. Lal Pathlabs Ltd - Updates

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

24-Jul-2017 12:48 PM

Dr. Lal Pathlabs Ltd - Shareholders meeting

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Proceedings of Annual General Meeting held on July 20, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

21-Jul-2017 06:14 PM

Dr. Lal Pathlabs Ltd - Statement Of Investor Complaints For The Quarter Ended June 30, 2017

With reference to the captioned subject, the details with respect to investor complaints for the quarter ended June 30, 2017 are as per the attachment.

10-Jul-2017 12:38 PM

Dr. Lal Pathlabs Ltd - Board Meeting On August 07, 2017

Dear Sir/Madam,

This is to inform you that a meeting of the Board of Directors is scheduled to be held on Monday, August 07, 2017 to inter-alia consider and approve the unaudited Financial Results of the Company for the Quarter ended June 30, 2017.

We further wish to inform you that the Trading Window, as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, will be closed from July 01, 2017 to August 09, 2017 for the purpose of announcement / declaration of such results by the Company.

We request you to kindly take the same on record.

30-Jun-2017 11:07 AM

Dr. Lal Pathlabs Ltd - Updates

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

24-Jul-2017 12:48 PM

Dr. Lal Pathlabs Ltd - Statement Of Investor Complaints For The Quarter Ended June 30, 2017

With reference to the captioned subject, the details with respect to investor complaints for the quarter ended June 30, 2017 are as per the attachment.

10-Jul-2017 12:38 PM

Dr. Lal Pathlabs Ltd - Board Meeting On August 07, 2017

Dear Sir/Madam,

This is to inform you that a meeting of the Board of Directors is scheduled to be held on Monday, August 07, 2017 to inter-alia consider and approve the unaudited Financial Results of the Company for the Quarter ended June 30, 2017.

We further wish to inform you that the Trading Window, as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, will be closed from July 01, 2017 to August 09, 2017 for the purpose of announcement / declaration of such results by the Company.

We request you to kindly take the same on record.

30-Jun-2017 11:07 AM

Corporate Details

About Management

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company.

Registered Office

12th Floor, Tower B, SAS Tower, Sector 38, Medicity,

0124-3016500,,,      0124-4234468,

cs@lalpathlabs.com

https://www.lalpathlabs.com

Registrar Details

Link Intime India Pvt. Ltd.